减少内源性铜和葡萄糖的可用性,用于级联饥饿疗法和化学动力疗法
Chunhui Wang1, Pingting Ye1, Mengyao Chen1
1School of Chemical Science and Engineering, Breast Cancer Center, Shanghai East Hospital, Tongji University, Shanghai, 200092, PR China.
Materials today. Bio
|April 15, 2025
概括
这项研究引入了一个纳米反应器,可以耗尽瘤营养物质,如葡萄糖和铜. 这种双重作用使癌细胞饥饿,并触发了级联化学动力学疗法,以加强瘤治疗.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 瘤生长取决于葡萄糖和铜等营养素.
- 向营养供应是癌症治疗的一个关键策略.
- 仅仅阻止营养供应可能无法消除瘤.
研究的目的:
- 设计一个多功能纳米反应器 (HPP/TPEN@GC) 来破坏瘤代谢.
- 通过准葡萄糖和铜来诱导级联化学动力学疗法 (CDT).
- 开发一种新的治疗范式,利用内生营养素.
主要方法:
- 合成了一种纳米反应器,其中使用了N,N,N',N'-tetrakis(2-pyridinylmethyl) -1,2-ethanediamine (TPEN) 和葡萄糖氧化酶 (GOx).
- 利用纳米反应器在瘤中耗尽内源葡萄糖和铜.
- 杆化纳米反应器活动以产生用于CDT的活性氧物种 (ROS).
主要成果:
- 降低葡萄糖和铜的可用性,阻碍糖解和线粒体代谢.
- 由于铜耗尽而导致线粒体复合体IV (CIV) 功能受损.
- 生成芬顿类催化剂和H2O2,导致基 (·OH) 生产.
- 实现了级联饥饿-化学动力学疗法.
结论:
- 纳米反应器有效地准瘤营养代谢.
- 这种方法结合了饥饿治疗和化学动力学治疗.
- 利用内源营养素为癌症治疗提供了一个有前途的策略.
相关概念视频
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


